| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 59 | 2025 | 874 | 7.890 |
Why?
|
| Pancreatic Neoplasms | 43 | 2026 | 944 | 4.700 |
Why?
|
| Antineoplastic Agents | 62 | 2024 | 2219 | 4.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 53 | 2026 | 1998 | 4.210 |
Why?
|
| Adenocarcinoma | 22 | 2026 | 927 | 2.960 |
Why?
|
| Neoplasms | 43 | 2022 | 2954 | 2.480 |
Why?
|
| Protein Kinase Inhibitors | 21 | 2020 | 983 | 2.200 |
Why?
|
| Xenograft Model Antitumor Assays | 35 | 2025 | 930 | 2.000 |
Why?
|
| Amyloid Precursor Protein Secretases | 7 | 2021 | 80 | 2.000 |
Why?
|
| Deoxycytidine | 19 | 2025 | 219 | 1.990 |
Why?
|
| Camptothecin | 19 | 2025 | 139 | 1.900 |
Why?
|
| Antibodies, Monoclonal, Humanized | 29 | 2025 | 992 | 1.800 |
Why?
|
| Liver Neoplasms | 11 | 2025 | 776 | 1.770 |
Why?
|
| Immunoconjugates | 12 | 2021 | 138 | 1.700 |
Why?
|
| Colonic Neoplasms | 11 | 2026 | 259 | 1.580 |
Why?
|
| Carcinoma, Pancreatic Ductal | 11 | 2025 | 297 | 1.520 |
Why?
|
| Antibodies, Monoclonal | 21 | 2024 | 1512 | 1.420 |
Why?
|
| Quinazolines | 11 | 2015 | 267 | 1.370 |
Why?
|
| Drug Resistance, Neoplasm | 16 | 2025 | 893 | 1.330 |
Why?
|
| Tetrahydronaphthalenes | 3 | 2017 | 34 | 1.320 |
Why?
|
| Valine | 3 | 2017 | 84 | 1.290 |
Why?
|
| ErbB Receptors | 14 | 2016 | 636 | 1.270 |
Why?
|
| src-Family Kinases | 4 | 2017 | 93 | 1.250 |
Why?
|
| Molecular Targeted Therapy | 11 | 2024 | 447 | 1.170 |
Why?
|
| ras Proteins | 10 | 2017 | 148 | 1.160 |
Why?
|
| Maximum Tolerated Dose | 23 | 2026 | 217 | 1.160 |
Why?
|
| Fluorouracil | 15 | 2025 | 231 | 1.110 |
Why?
|
| Rectal Neoplasms | 8 | 2024 | 160 | 1.060 |
Why?
|
| Enzyme Inhibitors | 9 | 2020 | 823 | 1.050 |
Why?
|
| Benzodioxoles | 5 | 2012 | 164 | 1.040 |
Why?
|
| Humans | 206 | 2026 | 146342 | 1.030 |
Why?
|
| Cetuximab | 11 | 2025 | 110 | 1.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 11 | 2018 | 384 | 0.990 |
Why?
|
| Mutation | 16 | 2026 | 4093 | 0.990 |
Why?
|
| Bevacizumab | 8 | 2024 | 169 | 0.960 |
Why?
|
| Biomarkers, Tumor | 14 | 2026 | 1339 | 0.900 |
Why?
|
| Aged | 82 | 2026 | 26432 | 0.900 |
Why?
|
| CD47 Antigen | 1 | 2025 | 41 | 0.900 |
Why?
|
| Pyridines | 9 | 2022 | 610 | 0.890 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2026 | 74 | 0.870 |
Why?
|
| Wnt Signaling Pathway | 8 | 2024 | 211 | 0.860 |
Why?
|
| Cell Line, Tumor | 33 | 2025 | 3545 | 0.860 |
Why?
|
| Proto-Oncogene Proteins | 13 | 2018 | 616 | 0.860 |
Why?
|
| Benzimidazoles | 7 | 2024 | 191 | 0.840 |
Why?
|
| Middle Aged | 88 | 2026 | 36619 | 0.830 |
Why?
|
| Neoadjuvant Therapy | 13 | 2026 | 475 | 0.820 |
Why?
|
| Anilides | 3 | 2022 | 83 | 0.810 |
Why?
|
| Receptor, Notch1 | 3 | 2015 | 62 | 0.810 |
Why?
|
| Aldehyde Dehydrogenase | 6 | 2017 | 98 | 0.810 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 139 | 0.780 |
Why?
|
| Drugs, Investigational | 2 | 2015 | 31 | 0.770 |
Why?
|
| Mice, Nude | 24 | 2024 | 668 | 0.760 |
Why?
|
| Signal Transduction | 22 | 2019 | 5246 | 0.760 |
Why?
|
| Aniline Compounds | 4 | 2011 | 120 | 0.750 |
Why?
|
| Immunotherapy | 5 | 2022 | 671 | 0.730 |
Why?
|
| Medical Oncology | 9 | 2025 | 345 | 0.720 |
Why?
|
| Female | 113 | 2026 | 79499 | 0.710 |
Why?
|
| Quinolines | 4 | 2022 | 191 | 0.700 |
Why?
|
| Treatment Outcome | 43 | 2026 | 11821 | 0.670 |
Why?
|
| Paclitaxel | 9 | 2025 | 260 | 0.660 |
Why?
|
| Nitriles | 3 | 2011 | 212 | 0.660 |
Why?
|
| Dose-Response Relationship, Drug | 23 | 2017 | 2022 | 0.650 |
Why?
|
| Neoplasm Metastasis | 16 | 2025 | 693 | 0.640 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2022 | 545 | 0.640 |
Why?
|
| Mice | 44 | 2025 | 18297 | 0.620 |
Why?
|
| Drug Design | 6 | 2022 | 180 | 0.620 |
Why?
|
| Carcinoma | 3 | 2011 | 225 | 0.610 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2020 | 200 | 0.600 |
Why?
|
| Sulfones | 4 | 2015 | 127 | 0.600 |
Why?
|
| Gene Dosage | 3 | 2015 | 146 | 0.600 |
Why?
|
| Adult | 70 | 2026 | 41087 | 0.600 |
Why?
|
| Dasatinib | 2 | 2017 | 58 | 0.590 |
Why?
|
| Administration, Oral | 14 | 2017 | 872 | 0.590 |
Why?
|
| Pancreatectomy | 4 | 2026 | 289 | 0.590 |
Why?
|
| Animals | 58 | 2025 | 38107 | 0.590 |
Why?
|
| Aged, 80 and over | 33 | 2026 | 8391 | 0.590 |
Why?
|
| Glycine | 4 | 2015 | 184 | 0.590 |
Why?
|
| Neoplasm Staging | 17 | 2024 | 1488 | 0.580 |
Why?
|
| Male | 87 | 2026 | 73396 | 0.570 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 246 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 1591 | 0.560 |
Why?
|
| Pyrimidinones | 4 | 2015 | 124 | 0.560 |
Why?
|
| MAP Kinase Kinase 1 | 3 | 2015 | 70 | 0.560 |
Why?
|
| Receptors, Notch | 3 | 2015 | 92 | 0.560 |
Why?
|
| Tumor Microenvironment | 7 | 2023 | 747 | 0.550 |
Why?
|
| Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.530 |
Why?
|
| Pyrimidines | 7 | 2022 | 532 | 0.530 |
Why?
|
| Liver Transplantation | 1 | 2025 | 751 | 0.530 |
Why?
|
| Pyridones | 4 | 2015 | 210 | 0.520 |
Why?
|
| Albumins | 6 | 2025 | 120 | 0.500 |
Why?
|
| DNA Helicases | 3 | 2024 | 138 | 0.490 |
Why?
|
| Phenylurea Compounds | 7 | 2022 | 122 | 0.490 |
Why?
|
| Benzazepines | 2 | 2014 | 36 | 0.490 |
Why?
|
| MAP Kinase Kinase Kinases | 4 | 2015 | 70 | 0.480 |
Why?
|
| Antigens, Neoplasm | 8 | 2018 | 271 | 0.470 |
Why?
|
| Disease Models, Animal | 10 | 2024 | 4580 | 0.470 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2025 | 663 | 0.460 |
Why?
|
| Autophagy | 1 | 2018 | 290 | 0.460 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2023 | 628 | 0.460 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2018 | 239 | 0.460 |
Why?
|
| MAP Kinase Kinase 2 | 2 | 2012 | 28 | 0.460 |
Why?
|
| Immunoglobulin Fc Fragments | 3 | 2021 | 41 | 0.450 |
Why?
|
| Apoptosis | 14 | 2022 | 2439 | 0.450 |
Why?
|
| Microsatellite Instability | 5 | 2025 | 57 | 0.440 |
Why?
|
| Drug Administration Schedule | 14 | 2017 | 790 | 0.440 |
Why?
|
| Patient Rights | 1 | 2015 | 11 | 0.440 |
Why?
|
| Disease-Free Survival | 11 | 2023 | 778 | 0.440 |
Why?
|
| Cell Proliferation | 18 | 2024 | 2502 | 0.440 |
Why?
|
| Therapies, Investigational | 1 | 2015 | 18 | 0.430 |
Why?
|
| Drug and Narcotic Control | 1 | 2015 | 24 | 0.430 |
Why?
|
| Combined Modality Therapy | 8 | 2024 | 1271 | 0.430 |
Why?
|
| 3' Untranslated Regions | 2 | 2012 | 152 | 0.430 |
Why?
|
| Leucovorin | 9 | 2025 | 98 | 0.420 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2026 | 429 | 0.420 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 192 | 0.420 |
Why?
|
| DNA-Binding Proteins | 5 | 2024 | 1468 | 0.410 |
Why?
|
| Receptors, Enterotoxin | 3 | 2026 | 4 | 0.410 |
Why?
|
| Azepines | 3 | 2020 | 104 | 0.390 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2014 | 288 | 0.380 |
Why?
|
| Prognosis | 10 | 2023 | 4351 | 0.370 |
Why?
|
| Epithelial-Mesenchymal Transition | 5 | 2021 | 219 | 0.370 |
Why?
|
| Methylurea Compounds | 3 | 2006 | 7 | 0.360 |
Why?
|
| Neutropenia | 7 | 2022 | 153 | 0.350 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 10 | 2019 | 250 | 0.350 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 5 | 2019 | 111 | 0.340 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2019 | 220 | 0.340 |
Why?
|
| Cell Adhesion Molecules | 5 | 2018 | 180 | 0.330 |
Why?
|
| Terminal Care | 1 | 2015 | 284 | 0.330 |
Why?
|
| Anus Neoplasms | 2 | 2023 | 33 | 0.320 |
Why?
|
| Gamma Rays | 2 | 2021 | 56 | 0.320 |
Why?
|
| Survival Rate | 9 | 2025 | 2092 | 0.320 |
Why?
|
| Area Under Curve | 9 | 2018 | 335 | 0.310 |
Why?
|
| Genes, ras | 2 | 2018 | 70 | 0.310 |
Why?
|
| Thymidylate Synthase | 1 | 2010 | 13 | 0.310 |
Why?
|
| Drug Synergism | 2 | 2024 | 354 | 0.300 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2018 | 455 | 0.300 |
Why?
|
| Faculty, Medical | 2 | 2025 | 309 | 0.300 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 149 | 0.300 |
Why?
|
| Phthalazines | 2 | 2023 | 64 | 0.300 |
Why?
|
| Immunoblotting | 6 | 2015 | 294 | 0.290 |
Why?
|
| Proto-Oncogene Proteins B-raf | 7 | 2026 | 231 | 0.290 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2010 | 190 | 0.280 |
Why?
|
| Immunohistochemistry | 9 | 2019 | 1712 | 0.270 |
Why?
|
| Cell Cycle Proteins | 5 | 2018 | 630 | 0.270 |
Why?
|
| Metabolic Clearance Rate | 6 | 2012 | 115 | 0.260 |
Why?
|
| Sirolimus | 4 | 2012 | 282 | 0.260 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 2019 | 24 | 0.260 |
Why?
|
| Organoplatinum Compounds | 6 | 2014 | 65 | 0.250 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 268 | 0.250 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2018 | 66 | 0.250 |
Why?
|
| Membrane Proteins | 6 | 2021 | 1130 | 0.250 |
Why?
|
| Clinical Trials as Topic | 8 | 2024 | 1064 | 0.250 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2020 | 233 | 0.250 |
Why?
|
| Pyrazoles | 4 | 2022 | 517 | 0.240 |
Why?
|
| Genetic Testing | 1 | 2009 | 492 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 3 | 2018 | 287 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 1160 | 0.240 |
Why?
|
| Diarrhea | 2 | 2026 | 190 | 0.240 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 1107 | 0.240 |
Why?
|
| Capecitabine | 4 | 2015 | 56 | 0.240 |
Why?
|
| CD3 Complex | 1 | 2026 | 113 | 0.240 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2026 | 28 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 87 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2020 | 1432 | 0.230 |
Why?
|
| Chemoembolization, Therapeutic | 3 | 2013 | 88 | 0.230 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2025 | 14 | 0.230 |
Why?
|
| Head and Neck Neoplasms | 3 | 2016 | 563 | 0.230 |
Why?
|
| Antibodies, Bispecific | 1 | 2026 | 70 | 0.230 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 2675 | 0.220 |
Why?
|
| Heterografts | 3 | 2021 | 143 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2018 | 441 | 0.220 |
Why?
|
| Mice, Inbred BALB C | 2 | 2025 | 1244 | 0.220 |
Why?
|
| Survival Analysis | 7 | 2017 | 1378 | 0.220 |
Why?
|
| Neoplasm Proteins | 4 | 2020 | 444 | 0.220 |
Why?
|
| Cyclosporine | 2 | 2018 | 256 | 0.210 |
Why?
|
| Neoplastic Stem Cells | 3 | 2018 | 403 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2017 | 1195 | 0.210 |
Why?
|
| Drug Discovery | 3 | 2016 | 154 | 0.210 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 307 | 0.210 |
Why?
|
| Collagen Type I | 1 | 2025 | 144 | 0.210 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 5439 | 0.210 |
Why?
|
| Sulfonamides | 4 | 2022 | 594 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2016 | 370 | 0.210 |
Why?
|
| Retrospective Studies | 14 | 2026 | 17438 | 0.210 |
Why?
|
| cdc25 Phosphatases | 1 | 2024 | 13 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2015 | 752 | 0.200 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2025 | 124 | 0.200 |
Why?
|
| Erlotinib Hydrochloride | 5 | 2015 | 71 | 0.200 |
Why?
|
| Societies, Medical | 2 | 2018 | 907 | 0.200 |
Why?
|
| Positron-Emission Tomography | 3 | 2018 | 343 | 0.200 |
Why?
|
| Oncologists | 1 | 2024 | 47 | 0.200 |
Why?
|
| STAT3 Transcription Factor | 3 | 2022 | 214 | 0.200 |
Why?
|
| DNA Mismatch Repair | 3 | 2021 | 54 | 0.190 |
Why?
|
| Subacute Care | 1 | 2024 | 85 | 0.190 |
Why?
|
| Metastasectomy | 1 | 2023 | 19 | 0.190 |
Why?
|
| TCF Transcription Factors | 2 | 2020 | 19 | 0.190 |
Why?
|
| Colon | 1 | 2005 | 304 | 0.190 |
Why?
|
| DNA | 1 | 2009 | 1421 | 0.190 |
Why?
|
| Perioperative Care | 1 | 2025 | 235 | 0.190 |
Why?
|
| DNA Mutational Analysis | 5 | 2012 | 410 | 0.190 |
Why?
|
| Collagen | 1 | 2025 | 460 | 0.190 |
Why?
|
| Pyrazines | 2 | 2018 | 94 | 0.180 |
Why?
|
| Cancer Care Facilities | 2 | 2016 | 48 | 0.180 |
Why?
|
| HCT116 Cells | 4 | 2018 | 78 | 0.180 |
Why?
|
| Ephrin-B2 | 2 | 2021 | 45 | 0.180 |
Why?
|
| Biopsy | 5 | 2023 | 1075 | 0.180 |
Why?
|
| Time Factors | 9 | 2017 | 7109 | 0.180 |
Why?
|
| Skilled Nursing Facilities | 1 | 2024 | 152 | 0.180 |
Why?
|
| DNA Topoisomerases, Type II | 3 | 2019 | 42 | 0.180 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 167 | 0.180 |
Why?
|
| Cell Cycle | 4 | 2018 | 595 | 0.180 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2006 | 778 | 0.180 |
Why?
|
| Forecasting | 1 | 2023 | 388 | 0.170 |
Why?
|
| Colic | 1 | 2001 | 10 | 0.170 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2023 | 44 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2025 | 970 | 0.170 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 64 | 0.170 |
Why?
|
| Tumor Burden | 5 | 2018 | 326 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 319 | 0.170 |
Why?
|
| Disease Management | 3 | 2024 | 651 | 0.170 |
Why?
|
| Infusions, Intravenous | 4 | 2017 | 432 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 5 | 2021 | 882 | 0.170 |
Why?
|
| Trastuzumab | 1 | 2021 | 119 | 0.170 |
Why?
|
| Radiosurgery | 2 | 2025 | 398 | 0.160 |
Why?
|
| ADAM10 Protein | 1 | 2021 | 29 | 0.160 |
Why?
|
| Tissue Distribution | 2 | 2012 | 334 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 103 | 0.160 |
Why?
|
| Gene Expression Profiling | 5 | 2024 | 1792 | 0.160 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2019 | 219 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 3 | 2020 | 335 | 0.160 |
Why?
|
| Abdomen | 1 | 2001 | 142 | 0.160 |
Why?
|
| Momordica charantia | 1 | 2020 | 14 | 0.160 |
Why?
|
| Cell Plasticity | 1 | 2021 | 37 | 0.160 |
Why?
|
| Aurora Kinase A | 2 | 2020 | 57 | 0.160 |
Why?
|
| Benzoxazoles | 1 | 2020 | 20 | 0.160 |
Why?
|
| Neoplasm Transplantation | 6 | 2018 | 238 | 0.160 |
Why?
|
| Topoisomerase I Inhibitors | 3 | 2017 | 20 | 0.160 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 122 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2012 | 334 | 0.150 |
Why?
|
| Diagnostic Errors | 1 | 2001 | 178 | 0.150 |
Why?
|
| Lymphoma | 1 | 2022 | 251 | 0.150 |
Why?
|
| Peptide Fragments | 1 | 2024 | 693 | 0.150 |
Why?
|
| Half-Life | 3 | 2017 | 157 | 0.150 |
Why?
|
| Imidazoles | 2 | 2018 | 245 | 0.150 |
Why?
|
| Immune System | 1 | 2021 | 181 | 0.150 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 78 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2021 | 149 | 0.150 |
Why?
|
| Intestinal Neoplasms | 1 | 2019 | 31 | 0.150 |
Why?
|
| Postoperative Complications | 2 | 2026 | 3034 | 0.150 |
Why?
|
| Disease Progression | 8 | 2025 | 2867 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 314 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 504 | 0.150 |
Why?
|
| Pancreas | 2 | 2022 | 343 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2017 | 178 | 0.140 |
Why?
|
| Benchmarking | 1 | 2020 | 193 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2020 | 108 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 597 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinase | 2 | 2016 | 24 | 0.140 |
Why?
|
| Receptor, EphB4 | 1 | 2019 | 33 | 0.140 |
Why?
|
| Benzamides | 3 | 2014 | 226 | 0.140 |
Why?
|
| Melanoma | 2 | 2018 | 765 | 0.140 |
Why?
|
| Oligopeptides | 2 | 2018 | 264 | 0.140 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2020 | 70 | 0.140 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2020 | 72 | 0.140 |
Why?
|
| CDC2 Protein Kinase | 1 | 2018 | 26 | 0.140 |
Why?
|
| United States | 10 | 2024 | 16136 | 0.140 |
Why?
|
| Plant Extracts | 1 | 2020 | 192 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2025 | 729 | 0.140 |
Why?
|
| Patient Compliance | 2 | 2021 | 589 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 104 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2019 | 160 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2010 | 2786 | 0.140 |
Why?
|
| Fibrosis | 1 | 2021 | 568 | 0.140 |
Why?
|
| Aminobenzoates | 1 | 2018 | 7 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 313 | 0.130 |
Why?
|
| Piperazines | 2 | 2022 | 368 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 530 | 0.130 |
Why?
|
| TWEAK Receptor | 1 | 2017 | 6 | 0.130 |
Why?
|
| Chemoradiotherapy | 4 | 2023 | 238 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2009 | 141 | 0.130 |
Why?
|
| Cytochrome P-450 CYP3A | 3 | 2008 | 93 | 0.130 |
Why?
|
| Communication | 1 | 2024 | 980 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2024 | 997 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2001 | 428 | 0.130 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 62 | 0.130 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 29 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 372 | 0.120 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2008 | 163 | 0.120 |
Why?
|
| beta Catenin | 2 | 2016 | 250 | 0.120 |
Why?
|
| Taxoids | 2 | 2008 | 115 | 0.120 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 109 | 0.120 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 51 | 0.120 |
Why?
|
| Physicians | 1 | 2025 | 955 | 0.120 |
Why?
|
| Guanylate Cyclase | 1 | 2016 | 36 | 0.120 |
Why?
|
| Niacinamide | 3 | 2012 | 103 | 0.120 |
Why?
|
| Tankyrases | 1 | 2016 | 13 | 0.120 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2016 | 26 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 320 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2017 | 178 | 0.120 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 3 | 2022 | 43 | 0.120 |
Why?
|
| Gonanes | 2 | 2013 | 23 | 0.120 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2015 | 30 | 0.110 |
Why?
|
| Myenteric Plexus | 1 | 1995 | 4 | 0.110 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.110 |
Why?
|
| Jagged-1 Protein | 1 | 2015 | 22 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2017 | 125 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2017 | 266 | 0.110 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2006 | 175 | 0.110 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 633 | 0.110 |
Why?
|
| Fluorocarbons | 2 | 2014 | 122 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 220 | 0.110 |
Why?
|
| Gene Duplication | 1 | 2015 | 67 | 0.110 |
Why?
|
| Device Approval | 1 | 2015 | 19 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 128 | 0.110 |
Why?
|
| Retinaldehyde | 1 | 2015 | 4 | 0.110 |
Why?
|
| Receptor, ErbB-3 | 1 | 2015 | 48 | 0.110 |
Why?
|
| RNA Interference | 3 | 2016 | 472 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2025 | 8123 | 0.110 |
Why?
|
| Cohort Studies | 7 | 2024 | 6077 | 0.110 |
Why?
|
| Acetaldehyde | 1 | 2015 | 18 | 0.110 |
Why?
|
| Young Adult | 8 | 2024 | 14330 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2015 | 166 | 0.110 |
Why?
|
| Acridines | 1 | 2014 | 10 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2024 | 2599 | 0.110 |
Why?
|
| Nitric Oxide Synthase | 1 | 1995 | 233 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2016 | 391 | 0.110 |
Why?
|
| Drug Approval | 1 | 2015 | 94 | 0.100 |
Why?
|
| Muscle, Smooth | 1 | 1995 | 152 | 0.100 |
Why?
|
| Fatigue | 4 | 2012 | 363 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2017 | 901 | 0.100 |
Why?
|
| Neuropilin-1 | 1 | 2014 | 8 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2020 | 194 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 2020 | 2791 | 0.100 |
Why?
|
| Piperidines | 1 | 2015 | 225 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 208 | 0.100 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 221 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 76 | 0.100 |
Why?
|
| Chromatography, Liquid | 2 | 2006 | 453 | 0.100 |
Why?
|
| Protein Binding | 2 | 2018 | 2244 | 0.100 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 47 | 0.100 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 54 | 0.100 |
Why?
|
| Sensitivity and Specificity | 5 | 2009 | 1998 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 194 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2017 | 462 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 487 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2022 | 415 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2006 | 576 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2012 | 8 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 351 | 0.090 |
Why?
|
| Random Allocation | 1 | 2013 | 366 | 0.090 |
Why?
|
| Patient Selection | 3 | 2018 | 728 | 0.090 |
Why?
|
| Uveal Neoplasms | 1 | 2012 | 16 | 0.090 |
Why?
|
| Demography | 2 | 2010 | 274 | 0.090 |
Why?
|
| Aldehyde Dehydrogenase, Mitochondrial | 3 | 2017 | 23 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 85 | 0.090 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 91 | 0.090 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 150 | 0.090 |
Why?
|
| Cholangiocarcinoma | 1 | 2013 | 110 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2019 | 1163 | 0.090 |
Why?
|
| Transplantation, Heterologous | 4 | 2016 | 165 | 0.080 |
Why?
|
| Polyneuropathies | 1 | 2011 | 57 | 0.080 |
Why?
|
| Exanthema | 2 | 2018 | 86 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2013 | 1177 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3926 | 0.080 |
Why?
|
| CA-19-9 Antigen | 1 | 2010 | 36 | 0.080 |
Why?
|
| Thiazoles | 1 | 2011 | 139 | 0.080 |
Why?
|
| Organoids | 2 | 2024 | 143 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 126 | 0.080 |
Why?
|
| Estrenes | 1 | 2010 | 12 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 371 | 0.080 |
Why?
|
| Hepatectomy | 2 | 2016 | 256 | 0.080 |
Why?
|
| Reproducibility of Results | 6 | 2010 | 3416 | 0.080 |
Why?
|
| DNA Primers | 2 | 2009 | 487 | 0.080 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2009 | 32 | 0.080 |
Why?
|
| Tissue Fixation | 1 | 2009 | 35 | 0.080 |
Why?
|
| Paraffin Embedding | 1 | 2009 | 33 | 0.080 |
Why?
|
| DNA Damage | 2 | 2024 | 439 | 0.070 |
Why?
|
| Homozygote | 1 | 2010 | 197 | 0.070 |
Why?
|
| Oncogene Protein pp60(v-src) | 1 | 2009 | 4 | 0.070 |
Why?
|
| Formaldehyde | 1 | 2009 | 66 | 0.070 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2009 | 14 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 231 | 0.070 |
Why?
|
| Caveolin 1 | 1 | 2009 | 20 | 0.070 |
Why?
|
| Cell Separation | 1 | 2010 | 300 | 0.070 |
Why?
|
| Oximes | 2 | 2022 | 26 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2001 | 2363 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2015 | 3712 | 0.070 |
Why?
|
| Aminoquinolines | 1 | 2008 | 18 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2012 | 399 | 0.070 |
Why?
|
| Dioxoles | 1 | 2008 | 9 | 0.070 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2008 | 8 | 0.070 |
Why?
|
| Watchful Waiting | 2 | 2019 | 90 | 0.070 |
Why?
|
| Dioxolanes | 1 | 2008 | 6 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 210 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 164 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 156 | 0.070 |
Why?
|
| Cytosine | 1 | 2008 | 49 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 66 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 377 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 1763 | 0.070 |
Why?
|
| Appointments and Schedules | 1 | 2008 | 97 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 419 | 0.060 |
Why?
|
| Colony-Stimulating Factors | 1 | 2007 | 37 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2009 | 311 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 974 | 0.060 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2008 | 90 | 0.060 |
Why?
|
| HT29 Cells | 2 | 2018 | 37 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 176 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 82 | 0.060 |
Why?
|
| Pyrroles | 2 | 2022 | 222 | 0.060 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2008 | 138 | 0.060 |
Why?
|
| Antimitotic Agents | 1 | 2006 | 8 | 0.060 |
Why?
|
| Benzenesulfonates | 1 | 2006 | 23 | 0.060 |
Why?
|
| Blood Cells | 1 | 2006 | 38 | 0.060 |
Why?
|
| Midazolam | 1 | 2006 | 69 | 0.060 |
Why?
|
| Gene Expression | 4 | 2019 | 1463 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 2 | 2006 | 166 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2023 | 6034 | 0.060 |
Why?
|
| Estradiol | 1 | 2010 | 517 | 0.060 |
Why?
|
| Intention to Treat Analysis | 1 | 2026 | 78 | 0.060 |
Why?
|
| Bortezomib | 1 | 2006 | 54 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 42 | 0.060 |
Why?
|
| Boronic Acids | 1 | 2006 | 37 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 161 | 0.060 |
Why?
|
| Incidence | 2 | 2026 | 2936 | 0.060 |
Why?
|
| Microsomes, Liver | 1 | 2005 | 85 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2012 | 699 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2010 | 594 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 640 | 0.060 |
Why?
|
| Risk Factors | 5 | 2026 | 10921 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2018 | 1724 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2005 | 117 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 806 | 0.050 |
Why?
|
| Spheroids, Cellular | 2 | 2016 | 81 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2006 | 155 | 0.050 |
Why?
|
| Genotype | 1 | 2010 | 1879 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 1224 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2006 | 239 | 0.050 |
Why?
|
| Anemia | 1 | 2006 | 190 | 0.050 |
Why?
|
| Rituximab | 1 | 2025 | 208 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2024 | 159 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 846 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 1432 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 76 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 3347 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 69 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 157 | 0.050 |
Why?
|
| Dogs | 3 | 2010 | 517 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 558 | 0.050 |
Why?
|
| Acetonitriles | 1 | 2022 | 12 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 2240 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 972 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2003 | 294 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2023 | 145 | 0.040 |
Why?
|
| G2 Phase | 2 | 2014 | 39 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2025 | 561 | 0.040 |
Why?
|
| Cisplatin | 1 | 2024 | 347 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1298 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2003 | 161 | 0.040 |
Why?
|
| Calibration | 3 | 2006 | 154 | 0.040 |
Why?
|
| Reference Standards | 3 | 2006 | 176 | 0.040 |
Why?
|
| Cell Division | 2 | 2016 | 736 | 0.040 |
Why?
|
| Oncogenes | 1 | 2022 | 113 | 0.040 |
Why?
|
| Medical Audit | 1 | 2001 | 78 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2001 | 178 | 0.040 |
Why?
|
| Chimerism | 1 | 2021 | 35 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2022 | 127 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2023 | 386 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2025 | 565 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2021 | 79 | 0.040 |
Why?
|
| Medical Records | 1 | 2001 | 193 | 0.040 |
Why?
|
| Algorithms | 2 | 2024 | 1849 | 0.040 |
Why?
|
| Lymphoid Tissue | 1 | 2021 | 82 | 0.040 |
Why?
|
| Biomarkers | 3 | 2019 | 4340 | 0.040 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2021 | 28 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 360 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 76 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2022 | 226 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 35 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2019 | 185 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 2005 | 1041 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2020 | 131 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 20 | 0.040 |
Why?
|
| Smad4 Protein | 1 | 2019 | 33 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 141 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 598 | 0.040 |
Why?
|
| Transcriptome | 2 | 2016 | 1068 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 113 | 0.040 |
Why?
|
| Survivorship | 1 | 2019 | 62 | 0.040 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 23 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 1036 | 0.040 |
Why?
|
| Research Personnel | 1 | 2020 | 190 | 0.030 |
Why?
|
| Colostomy | 1 | 2018 | 28 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 563 | 0.030 |
Why?
|
| 4-Aminobenzoic Acid | 1 | 2018 | 8 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 179 | 0.030 |
Why?
|
| Calcium | 2 | 2013 | 1181 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2009 | 2113 | 0.030 |
Why?
|
| Rats | 3 | 2010 | 5586 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2019 | 209 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 87 | 0.030 |
Why?
|
| Adolescent | 3 | 2024 | 22557 | 0.030 |
Why?
|
| Anal Canal | 1 | 2018 | 101 | 0.030 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2017 | 15 | 0.030 |
Why?
|
| Adenine | 1 | 2020 | 339 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2017 | 18 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 21 | 0.030 |
Why?
|
| RNA | 1 | 2024 | 926 | 0.030 |
Why?
|
| Education | 1 | 2017 | 103 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 79 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 494 | 0.030 |
Why?
|
| fas Receptor | 1 | 1997 | 91 | 0.030 |
Why?
|
| Protein Transport | 1 | 2018 | 443 | 0.030 |
Why?
|
| Rectum | 1 | 2018 | 180 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1361 | 0.030 |
Why?
|
| Esophagogastric Junction | 1 | 2017 | 54 | 0.030 |
Why?
|
| Retinal Dehydrogenase | 1 | 2016 | 27 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 90 | 0.030 |
Why?
|
| Axin Protein | 1 | 2016 | 18 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 143 | 0.030 |
Why?
|
| Cell Movement | 1 | 2021 | 951 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 105 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 104 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 49 | 0.030 |
Why?
|
| Leadership | 1 | 2020 | 414 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 54 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2016 | 113 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 139 | 0.030 |
Why?
|
| Flavin Mononucleotide | 1 | 1995 | 7 | 0.030 |
Why?
|
| Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 1995 | 4 | 0.030 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 1995 | 8 | 0.030 |
Why?
|
| Palliative Care | 1 | 2024 | 1032 | 0.030 |
Why?
|
| Polymyositis | 1 | 1995 | 13 | 0.030 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 1995 | 15 | 0.030 |
Why?
|
| NADP | 1 | 1995 | 52 | 0.030 |
Why?
|
| Dermatomyositis | 1 | 1995 | 24 | 0.030 |
Why?
|
| Ligands | 1 | 2017 | 678 | 0.030 |
Why?
|
| Calmodulin | 1 | 1995 | 70 | 0.030 |
Why?
|
| History, Ancient | 1 | 2015 | 54 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1503 | 0.030 |
Why?
|
| Diphenylamine | 1 | 2014 | 7 | 0.030 |
Why?
|
| Citrulline | 1 | 1995 | 45 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1995 | 103 | 0.030 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2014 | 23 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 202 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 18 | 0.030 |
Why?
|
| Acid Phosphatase | 1 | 2014 | 15 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 376 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 704 | 0.030 |
Why?
|
| Myositis | 1 | 1995 | 57 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 266 | 0.030 |
Why?
|
| Rhodamines | 1 | 2014 | 20 | 0.030 |
Why?
|
| Oxaloacetates | 1 | 2014 | 2 | 0.030 |
Why?
|
| Ileum | 1 | 1995 | 112 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 61 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1995 | 451 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 441 | 0.030 |
Why?
|
| Tretinoin | 1 | 2015 | 115 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 95 | 0.030 |
Why?
|
| Histones | 2 | 2010 | 670 | 0.030 |
Why?
|
| Arginine | 1 | 1995 | 264 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1331 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 3125 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 853 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1543 | 0.020 |
Why?
|
| Transfection | 1 | 2016 | 916 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 2921 | 0.020 |
Why?
|
| Receptor, Notch2 | 1 | 2013 | 15 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2016 | 560 | 0.020 |
Why?
|
| Neutrophils | 1 | 2019 | 1133 | 0.020 |
Why?
|
| Alphapapillomavirus | 1 | 2013 | 35 | 0.020 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2013 | 62 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1997 | 467 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 841 | 0.020 |
Why?
|
| Receptors, CXCR | 1 | 2012 | 5 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 931 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 3206 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 6073 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 64 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2014 | 372 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2018 | 701 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 517 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 2126 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 457 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 1997 | 435 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2012 | 62 | 0.020 |
Why?
|
| Nausea | 1 | 2012 | 111 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 1051 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 96 | 0.020 |
Why?
|
| Antioxidants | 1 | 1995 | 544 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 2013 | 132 | 0.020 |
Why?
|
| Vomiting | 1 | 2012 | 131 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 1493 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2013 | 246 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 1761 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2010 | 25 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 157 | 0.020 |
Why?
|
| Thalidomide | 1 | 2010 | 43 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2016 | 725 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 206 | 0.020 |
Why?
|
| Lung | 1 | 2023 | 4122 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2010 | 190 | 0.020 |
Why?
|
| Paxillin | 1 | 2009 | 11 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 1574 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2009 | 32 | 0.020 |
Why?
|
| Infliximab | 1 | 2009 | 107 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2009 | 49 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 1888 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 543 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 2012 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 2008 | 101 | 0.020 |
Why?
|
| Computational Biology | 1 | 2013 | 678 | 0.020 |
Why?
|
| Indoles | 1 | 2012 | 511 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2009 | 340 | 0.020 |
Why?
|
| Staurosporine | 1 | 2007 | 22 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 262 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 309 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2008 | 154 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 1 | 2006 | 27 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 496 | 0.020 |
Why?
|
| Celecoxib | 1 | 2006 | 41 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2006 | 61 | 0.020 |
Why?
|
| Clinical Chemistry Tests | 1 | 2006 | 6 | 0.020 |
Why?
|
| Hepatic Artery | 1 | 2006 | 53 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2006 | 115 | 0.010 |
Why?
|
| Leukocytes | 1 | 2008 | 301 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2006 | 179 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 170 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 70 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 585 | 0.010 |
Why?
|
| HIV Protease Inhibitors | 1 | 2005 | 69 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 237 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2009 | 784 | 0.010 |
Why?
|
| Ritonavir | 1 | 2005 | 76 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2006 | 484 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2005 | 389 | 0.010 |
Why?
|
| Tubulin | 1 | 2005 | 124 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 588 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 3017 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2008 | 1135 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 1553 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2008 | 996 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 493 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 2814 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 729 | 0.010 |
Why?
|
| Hypertension | 1 | 2010 | 1272 | 0.010 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1997 | 21 | 0.010 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1997 | 27 | 0.010 |
Why?
|
| Myelin Basic Protein | 1 | 1997 | 44 | 0.010 |
Why?
|
| Clone Cells | 1 | 1997 | 259 | 0.010 |
Why?
|
| Cell Death | 1 | 1997 | 379 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1997 | 330 | 0.010 |
Why?
|
| Multigene Family | 1 | 1995 | 210 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1995 | 360 | 0.010 |
Why?
|
| Autoantigens | 1 | 1997 | 426 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 2123 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 2092 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 2838 | 0.010 |
Why?
|